Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: A secondary end point of the CHICAGO study

Department of Medicine, Division of Cardiology, Pritzker School of Medicine, The University of Chicago, 515 N State St, Ste 2700, Chicago, IL 60654, USA.
Arteriosclerosis Thrombosis and Vascular Biology (Impact Factor: 6). 09/2010; 30(9):1873-6. DOI: 10.1161/ATVBAHA.110.207696
Source: PubMed


To compare coronary artery calcium (CAC) progression between 2 treatment groups, pioglitazone versus glimepiride.
The CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) study demonstrated that pioglitazone significantly decreased carotid intima-media thickness progression compared with glimepiride in patients with type 2 diabetes mellitus. The CAC level was determined at baseline and at the end of 72 weeks of treatment in the pioglitazone (n=146) and glimepiride (n=153) treatment groups using electron beam computed tomography. There was no difference in CAC progression between the treatment groups. By using backward and forward selection models, age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression. There was no relationship between carotid intima-media thickness and CAC progression during the study.
There was no difference in CAC progression in patients with type 2 diabetes mellitus treated with pioglitazone or glimepiride. Age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression in patients with type 2 diabetes mellitus.

Download full-text


Available from: Michael H Davidson, Sep 27, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the ligand-activated nuclear receptor family. Thiazolidinediones, such as rosiglitazone and pioglitazone, are synthetic agonists selective for PPARγ and have been used in the clinical treatment of type 2 diabetes. However, beyond the metabolic effects on glycemic control, PPARγ and its ligands also have profound effects on cardiovascular biological and pathophysiological processes. As cardiovascular diseases are closely associated with insulin resistance, and the major cause of death and complications of type 2 diabetes, a comprehensive understanding of the cardiovascular roles of this receptor is critical for the rational application of the existing agonists and the future development of therapeutic modulators. Therefore, this review will focus on the recent advances regarding the cardiovascular functions of PPARγ and its recognized effects on major cardiovascular diseases, in particular, atherosclerosis and associated processes.
    Circulation Journal 02/2011; 75(3):528-35. DOI:10.1253/circj.CJ-11-0060 · 3.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of cardiovascular risk reduction in patients with diabetes mellitus is significant as several factors have been found to promote accelerated atherosclerosis in persons with diabetes including hyperglycemia-induced endothelial dysfunction, impaired fibrinolysis, increased platelet aggregation, plaque instability, dysfunctional arterial remodeling, and fibrotic and calcified coronary arteries. Recent attention has focused on identifying a cardiovascular biomarker that would propose a better noninvasive way to detect or visualize subclinical cardiovascular disease and prevent cardiovascular events. This article reviews the use of commonly used cardiovascular risk assessment tools and emerging biomarkers including coronary artery calcium scanning, metabolomics, genomics, and the role of optimal revascularization and risk reduction strategies and their impact on reducing risk in patients with cardiovascular disease and diabetes.
    The American journal of cardiology 08/2011; 108(3 Suppl):42B-51B. DOI:10.1016/j.amjcard.2011.03.015 · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Peroxisome proliferator-activated receptor γ (PPAR-γ) is a key regulator of fatty acid metabolism, promoting its storage in adipose tissue and reducing circulating concentrations of free fatty acids. Activation of PPAR-γ has favorable effects on measures of adipocyte function, insulin sensitivity, lipoprotein metabolism, and vascular structure and function. Despite these effects, clinical trials of thiazolidinedione PPAR-γ activators have not provided conclusive evidence that they reduce cardiovascular morbidity and mortality. The apparent disparity between effects on laboratory measurements and clinical outcomes may be related to limitations of clinical trials, adverse effects of PPAR-γ activation, or off-target effects of thiazolidinedione agents. This review addresses these issues from a clinician's perspective and highlights several ongoing clinical trials that may help to clarify the therapeutic role of PPAR-γ activators in cardiovascular disease.
    The Journal of Lipid Research 06/2012; 53(9):1738-54. DOI:10.1194/jlr.R024505 · 4.42 Impact Factor